Neuralstem taking steps to expand pipeline

US biotech firm Neuralstem (Nasdaq: CUR), focused on the development of cell-based and small molecular therapeutic for central nervous system indications, has announced the initiation of a program to expand its current pipeline of therapeutic products.

The strategic move comes on the heels of the appointment of Kenneth Carter as executive chairman. Dr Carter previously served as the chief executive of various biopharmaceutical companies, including Avalon Pharmaceuticals and Neximmune.

"Neuralstem is focused on the continued development of its current technologies," said Dr Carter. "However, we have engaged a network of trusted experts and advisors to assist us in evaluating new technologies. To date, this initiative has identified certain preclinical and clinical stage assets that we believe, if developed, could create significant value for shareholders while expanding and diversifying our product pipeline," he added.